Enhancement of Periodontal Disease Management Strategies in Individuals With Chronic Hepatitis C Following Attainment of a Sustained Virological Response
DOI:
https://doi.org/10.5281/zenodo.20130849Ключевые слова:
chronic hepatitis C (CHC), direct-acting antivirals (DAAs), sustained virological response (SVR), hepatitis C virus (HCV), periodontal diseases, dental rehabilitationАннотация
The necessity of dental rehabilitation in patients with chronic hepatitis C (CHC) successfully treated with direct-
acting antivirals (DAAs) is analyzed. Despite viral eradication and the achievement of a sustained virological response
(SVR), pathological changes in periodontal tissues often persist. The study presents an approach aimed at developing
a comprehensive treatment algorithm that takes into account the local immunological status and the functional hepatic
reserve of patients
Библиографические ссылки
1. World Health Organization. Global Report on Health Data Systems and Capacity for Viral Hepatitis: Goals for 2030. –
Geneva: WHO, 2024.
2. Nagao Y., Kawahara K., Kawahara M. Impact of systemic inflammation on oral health in patients with chronic hepatitis
C after viral eradication by direct-acting antivirals // Journal of Clinical Medicine. – 2022. – Vol. 11, No. 14. – P. 4052.
3. Gigliotti J., Perillo L., Castiglia G., et al. Periodontal health and hepatitis C virus: A systematic review and meta-analysis
of the post-DAA era // Journal of Periodontology. – 2024. – Vol. 95, No. 3. – P. 215–228.
4. Carrozzo M., Francia S. Oral manifestations of hepatitis C virus infection: An update // Oral Diseases. – 2023. – Vol.
29, Suppl. 1. – P. 12–25.
5. Makhmudova U. B., Samatov A. A. Specifics of dental status in patients with chronic viral hepatitis C in the Samarkand
region // Journal of Hepato-Gastroenterology Research. – 2025. – Vol. 6, No. 2. – P. 45–51.
6. Shoukat S., Ahmed R., Khan M. Pro-inflammatory cytokine profiles in oral fluid as predictors of periodontal destruction
in post-HCV patients // International Journal of Dental Research. – 2024. – Vol. 12, No. 1. – P. 88–94.
7. Sutton A. J., Edmunds W. J., Gill O. N. Long-term outcomes and “immunological scarring” following successful DAA
therapy for hepatitis C // Lancet Gastroenterology & Hepatology. – 2023. – Vol. 8, No. 5. – P. 441–453.
8. Borgia G., Gentile I. Direct-acting antivirals and extrahepatic manifestations: A new paradigm in HCV management //
World Journal of Hepatology. – 2024. – Vol. 16, No. 4. – P. 112–120.
9. Lalla E., Papapanou P. N. Diabetes, hepatitis, and periodontal disease: The common inflammatory link // Periodontology
2000. – 2023. – Vol. 91, No. 1. – P. 135–152.
10. Zhamoityn A., Sadykova G. Evaluation of liver fibrosis using FibroScan in patients with periodontal disease: A
cross-sectional study // Central Asian Journal of Medicine. – 2025. – Vol. 9, No. 1. – P. 30–38.
11. Gomez R., Martinez M. The role of secretory IgA and lysozyme in the oral defense of patients after viral hepatitis treatment
// Oral Health and Preventive Dentistry. – 2025. – Vol. 23, No. 2. – P. 155–163.
12. Porphyromonas gingivalis and the systemic inflammatory burden: A focus on hepatobiliary patients // Journal of Dental
Research. – 2024. – Vol. 103, No. 6. – P. 541–550.
13. Bedossa P. Liver fibrosis and the METAVIR score: Clinical implications for multidisciplinary care // Clinical Liver Disease.
– 2023. – Vol. 27, No. 2. – P. 201–215.
14. Ismoilov S. I., et al. Epidemiological features of parenteral hepatitis in Uzbekistan: Current trends and challenges //
Uzbek Medical Journal. – 2024. – Vol. 5, No. 3. – P. 10–18.
15. GraphPad Software. Statistical Analysis of Clinical Data in Periodontal Research. – 10th ed. – San Diego, 2024.
Загрузки
Опубликован
Выпуск
Раздел
Лицензия
Copyright (c) 2026 MAKTABGACHA VA MAKTAB TA’LIMI JURNALI
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
